{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937929",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937929_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-magnitude\">modestly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"acalabrutinib\" outputclass=\"int-drug\">acalabrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   -containing antacids   modestly   decreases   the exposure to   oral   acalabrutinib .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acalabrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937930",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937930_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"alendronate\" outputclass=\"int-drug\">alendronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"alendronate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/alendronic-acid.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP4656\">alendronate</xref></ph> should be taken at least 30 minutes before <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93602\">calcium carbonate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   decreases   the absorption of   alendronate .  Manufacturer advises  alendronate  should be taken at least 30 minutes before  calcium carbonate .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alendronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937931",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937931_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of the active metabolite of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"baloxavir marboxil\" outputclass=\"int-drug\">baloxavir marboxil</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   might   decrease   the concentration of the active metabolite of   oral   baloxavir marboxil .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Baloxavir marboxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937932",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937932_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">Bendroflumethiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bendroflumethiazide   increases   the risk of hypercalcaemia when given with   calcium carbonate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937933",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937933_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"bosutinib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/bosutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33920\">bosutinib</xref></ph> should be taken at least 12 hours before antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   -containing antacids   are predicted to   decrease   the absorption of   oral   bosutinib .  Manufacturer advises  bosutinib  should be taken at least 12 hours before antacids .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937934",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937934_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"chloroquine\" outputclass=\"int-drug\">chloroquine</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 4 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   might   decrease   the absorption of   chloroquine .  Manufacturer advises separate administration by at least 4 hours .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chloroquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937935",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937935_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">Chlorothiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlorothiazide   increases   the risk of hypercalcaemia when given with   calcium carbonate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937936",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937936_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">Chlortalidone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlortalidone   increases   the risk of hypercalcaemia when given with   calcium carbonate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937937",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937937_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"ciprofloxacin\" outputclass=\"int-drug\">ciprofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   decreases   the absorption of   ciprofloxacin .  Manufacturer advises separate administration by 2 hours .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciprofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937938",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937938_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"clodronate\" outputclass=\"int-drug\">clodronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93602\">calcium carbonate</xref></ph> for 2 hours before or 1 hour after <ph otherprops=\"clodronate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/sodium-clodronate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP4681\">clodronate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   decreases   the absorption of   clodronate .  Manufacturer advises avoid  calcium carbonate  for 2 hours before or 1 hour after  clodronate .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clodronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937939",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937939_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   -containing antacids   are predicted to   decrease   the exposure to   oral   dasatinib .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937940",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937940_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"demeclocycline\" outputclass=\"int-drug\">demeclocycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 to 3 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   is predicted to   decrease   the absorption of   demeclocycline .  Manufacturer advises separate administration by 2 to 3 hours .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Demeclocycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937941",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937941_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Intravenous</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"digoxin\" outputclass=\"int-drug\">digoxin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Intravenous   calcium carbonate   increases   the effects of   digoxin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Digoxin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937942",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937942_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dolutegravir\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> should be taken 2 hours before or 6 hours after <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93602\">calcium carbonate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   decreases   the absorption of   dolutegravir .  Manufacturer advises  dolutegravir  should be taken 2 hours before or 6 hours after  calcium carbonate .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dolutegravir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937943",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937943_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"doxycycline\" outputclass=\"int-drug\">doxycycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 to 3 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   is predicted to   decrease   the absorption of   doxycycline .  Manufacturer advises separate administration by 2 to 3 hours .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxycycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937944",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937944_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93602\">calcium carbonate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   decreases   the absorption of   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after  calcium carbonate .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eltrombopag</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937945",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937945_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"erlotinib\" outputclass=\"int-drug\">erlotinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"erlotinib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/erlotinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5529\">erlotinib</xref></ph> should be taken 2 hours before or 4 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   -containing antacids   are predicted to   decrease   the absorption of   oral   erlotinib .  Manufacturer advises  erlotinib  should be taken 2 hours before or 4 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erlotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937946",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937946_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"estramustine\" outputclass=\"int-drug\">estramustine</ph>. <ph outputclass=\"int-action\">Manufacturer advises separating administration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   decreases   the absorption of   estramustine .  Manufacturer advises separating administration .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Estramustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937947",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937947_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"gefitinib\" outputclass=\"int-drug\">gefitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   -containing antacids   are predicted to   decrease   the exposure to   oral   gefitinib .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gefitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937948",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937948_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">Hydrochlorothiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrochlorothiazide   increases   the risk of hypercalcaemia when given with   calcium carbonate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937949",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937949_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">Hydroflumethiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydroflumethiazide   increases   the risk of hypercalcaemia when given with   calcium carbonate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937950",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937950_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"hydroxychloroquine\" outputclass=\"int-drug\">hydroxychloroquine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   is predicted to   decrease   the absorption of   hydroxychloroquine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxychloroquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937951",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937951_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"ibandronate\" outputclass=\"int-drug\">ibandronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93602\">calcium carbonate</xref></ph> for at least 6 hours before or 1 hour after <ph otherprops=\"ibandronate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/ibandronic-acid.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP4671\">ibandronate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   is predicted to   decrease   the absorption of   oral   ibandronate .  Manufacturer advises avoid  calcium carbonate  for at least 6 hours before or 1 hour after  ibandronate .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibandronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937952",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937952_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indapamide\" outputclass=\"int-drug\">Indapamide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indapamide   increases   the risk of hypercalcaemia when given with   calcium carbonate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937953",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937953_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"iron\" outputclass=\"int-drug\">iron</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93602\">calcium carbonate</xref></ph> should be taken 1 hour before or 2 hours after iron</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   decreases   the absorption of   oral   iron .  Manufacturer advises  calcium carbonate  should be taken 1 hour before or 2 hours after iron .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937954",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937954_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"lapatinib\" outputclass=\"int-drug\">lapatinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   -containing antacids   are predicted to   decrease   the absorption of   oral   lapatinib .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lapatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937955",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937955_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ledipasvir\" outputclass=\"int-drug\">ledipasvir</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 4 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   is predicted to   decrease   the exposure to   ledipasvir .  Manufacturer advises separate administration by 4 hours .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ledipasvir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937956",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937956_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"levothyroxine\" outputclass=\"int-drug\">levothyroxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 4 hours</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   is predicted to   decrease   the absorption of   levothyroxine .  Manufacturer advises separate administration by at least 4 hours .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levothyroxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937957",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937957_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"lymecycline\" outputclass=\"int-drug\">lymecycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 to 3 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   is predicted to   decrease   the absorption of   lymecycline .  Manufacturer advises separate administration by 2 to 3 hours .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lymecycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937958",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937958_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metolazone\" outputclass=\"int-drug\">Metolazone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Metolazone   increases   the risk of hypercalcaemia when given with   calcium carbonate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937959",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937959_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"minocycline\" outputclass=\"int-drug\">minocycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 to 3 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   is predicted to   decrease   the absorption of   minocycline .  Manufacturer advises separate administration by 2 to 3 hours .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Minocycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937960",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937960_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"neratinib\" outputclass=\"int-drug\">neratinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 3 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   -containing antacids   are predicted to   decrease   the exposure to   oral   neratinib .  Manufacturer advises separate administration by at least 3 hours .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Neratinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937961",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937961_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">affect</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   -containing antacids   might   affect   the exposure to   oral   nilotinib .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937962",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937962_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"oxytetracycline\" outputclass=\"int-drug\">oxytetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 to 3 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   is predicted to   decrease   the absorption of   oxytetracycline .  Manufacturer advises separate administration by 2 to 3 hours .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxytetracycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937963",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937963_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"pazopanib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/pazopanib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5542\">pazopanib</xref></ph> should be taken 1 hour before or 2 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   -containing antacids   might   decrease   the absorption of   oral   pazopanib .  Manufacturer advises  pazopanib  should be taken 1 hour before or 2 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937964",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937964_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"proguanil\" outputclass=\"int-drug\">proguanil</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   is predicted to   decrease   the absorption of   proguanil .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Proguanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937965",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937965_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-magnitude\">greatly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-drug\">raltegravir</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   greatly   decreases   the exposure to   raltegravir   (high-dose) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Raltegravir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937966",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937966_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"rilpivirine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/rilpivirine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3830\">rilpivirine</xref></ph> should be taken 4 hours before or 2 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   -containing antacids   are predicted to   decrease   the exposure to   oral   rilpivirine .  Manufacturer advises  rilpivirine  should be taken 4 hours before or 2 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rilpivirine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937967",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937967_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"risedronate\" outputclass=\"int-drug\">risedronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   decreases   the absorption of   risedronate .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risedronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937968",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937968_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"sotorasib\" outputclass=\"int-drug\">sotorasib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"sotorasib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/sotorasib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP223696\">sotorasib</xref></ph> should be taken 4 hours before or 10 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   is predicted to   decrease   the exposure to   oral   sotorasib .  Manufacturer advises  sotorasib  should be taken 4 hours before or 10 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotorasib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937969",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937969_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"strontium\" outputclass=\"int-drug\">strontium</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   decreases   the exposure to   strontium .  Manufacturer advises separate administration by 2 hours .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Strontium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937970",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937970_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"tetracycline\" outputclass=\"int-drug\">tetracycline</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 to 3 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   is predicted to   decrease   the absorption of   tetracycline .  Manufacturer advises separate administration by 2 to 3 hours .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetracycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937971",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937971_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">Calcium carbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"velpatasvir\" outputclass=\"int-drug\">velpatasvir</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 4 hours</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   is predicted to   decrease   the concentration of   velpatasvir .  Manufacturer advises separate administration by 4 hours .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Velpatasvir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937972",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937972_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"xipamide\" outputclass=\"int-drug\">Xipamide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Xipamide   increases   the risk of hypercalcaemia when given with   calcium carbonate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937973",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2#bnf_i1643857937973_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-heading-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"zinc\" outputclass=\"int-drug\">zinc</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   decreases   the absorption of   zinc .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zinc</title>"
					}
				}
			],
			"hasSearchLabel": " Calcium carbonate  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/calcium-carbonate-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Calcium carbonate </title>"
			},
			"rdfs:label": "calcium carbonate"
		}
	]
}